ECSP056202A - Derivados de imidazol como antagonistas del receptor del glutamato - Google Patents
Derivados de imidazol como antagonistas del receptor del glutamatoInfo
- Publication number
- ECSP056202A ECSP056202A EC2005006202A ECSP056202A ECSP056202A EC SP056202 A ECSP056202 A EC SP056202A EC 2005006202 A EC2005006202 A EC 2005006202A EC SP056202 A ECSP056202 A EC SP056202A EC SP056202 A ECSP056202 A EC SP056202A
- Authority
- EC
- Ecuador
- Prior art keywords
- antagonists
- derivatives
- imidazol
- glutamate
- receiver
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a derivados del imidazol que son antagonistas del receptor mGluR5, los cuales están representados por la fórmula general I, en donde R1, R2, R3 y R4 son como se han definido en la especificación, a un procedimiento para la obtención de los mismos, así como también a las sales farmacéuticamente aceptables de los mismos para la elaboración de un medicamento para el tratamiento o prevención de trastornos inducidos por el receptor mGluR5, tales como trastornos neurológicos agudos y/o crónicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03012200 | 2003-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP056202A true ECSP056202A (es) | 2006-04-19 |
Family
ID=33483899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005006202A ECSP056202A (es) | 2003-06-05 | 2005-12-02 | Derivados de imidazol como antagonistas del receptor del glutamato |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US7332510B2 (es) |
| EP (1) | EP1636206B1 (es) |
| JP (1) | JP4401384B2 (es) |
| KR (1) | KR100778948B1 (es) |
| CN (1) | CN100408572C (es) |
| AR (1) | AR044478A1 (es) |
| AT (1) | ATE377008T1 (es) |
| AU (1) | AU2004245208B2 (es) |
| BR (1) | BRPI0411095B8 (es) |
| CA (1) | CA2527315C (es) |
| CL (1) | CL2004001347A1 (es) |
| CR (1) | CR8094A (es) |
| CY (1) | CY1107856T1 (es) |
| DE (1) | DE602004009796T2 (es) |
| DK (1) | DK1636206T3 (es) |
| EA (1) | EA010577B1 (es) |
| EC (1) | ECSP056202A (es) |
| ES (1) | ES2294504T3 (es) |
| GT (1) | GT200400117A (es) |
| HN (1) | HN2004000208A (es) |
| HR (1) | HRP20070529T3 (es) |
| IL (1) | IL171930A (es) |
| MA (1) | MA27881A1 (es) |
| MX (1) | MXPA05013149A (es) |
| MY (2) | MY137272A (es) |
| NO (1) | NO332143B1 (es) |
| NZ (1) | NZ543637A (es) |
| PA (1) | PA8604101A1 (es) |
| PE (1) | PE20050162A1 (es) |
| PL (1) | PL1636206T3 (es) |
| PT (1) | PT1636206E (es) |
| RS (1) | RS53183B (es) |
| SI (1) | SI1636206T1 (es) |
| TN (2) | TNSN05309A1 (es) |
| TW (1) | TWI338007B (es) |
| UA (1) | UA80888C2 (es) |
| WO (1) | WO2004108701A1 (es) |
| ZA (2) | ZA200509807B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| US7452909B2 (en) | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| NZ551253A (en) | 2004-06-01 | 2010-07-30 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
| MY148217A (en) * | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
| US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| AU2012232711B2 (en) | 2011-03-18 | 2016-04-28 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
| MY171517A (en) * | 2012-10-18 | 2019-10-16 | Hoffmann La Roche | Ethynyl derivatives as modulators of mglur5 receptor activity |
| WO2014060398A1 (en) * | 2012-10-18 | 2014-04-24 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
| EP3436009B1 (en) * | 2016-03-30 | 2024-03-06 | Sinntaxis AB | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages. |
| EP4069685A1 (en) * | 2019-12-02 | 2022-10-12 | F. Hoffmann-La Roche AG | Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors |
| BR112022024760A2 (pt) | 2020-06-05 | 2023-03-07 | Noema Pharma Ag | Métodos de tratamento do complexo de esclerose tuberosa |
| BR112023001621A2 (pt) * | 2020-07-30 | 2023-04-04 | Noema Pharma Ag | Métodos de tratamento de neuralgia trigeminal |
| EP4658268A1 (en) | 2023-02-02 | 2025-12-10 | Noema Pharma AG | Methods of treatment of dravet syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508560A (en) | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| JP4815083B2 (ja) | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ，インコーポレイテッド | 神経栄養活性を有する置換５−アルキニルピリミジン |
| WO2002046166A1 (en) | 2000-12-04 | 2002-06-13 | F. Hoffmann-La Roche Ag | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| WO2003053922A2 (en) * | 2001-12-19 | 2003-07-03 | Merck & Co., Inc. | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| JP2006513996A (ja) * | 2002-10-24 | 2006-04-27 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体 |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| US7091222B2 (en) * | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
-
2004
- 2004-01-06 UA UAA200512695A patent/UA80888C2/uk unknown
- 2004-06-01 PT PT04739484T patent/PT1636206E/pt unknown
- 2004-06-01 JP JP2006508238A patent/JP4401384B2/ja not_active Expired - Lifetime
- 2004-06-01 PL PL04739484T patent/PL1636206T3/pl unknown
- 2004-06-01 SI SI200430525T patent/SI1636206T1/sl unknown
- 2004-06-01 DK DK04739484T patent/DK1636206T3/da active
- 2004-06-01 EP EP04739484A patent/EP1636206B1/en not_active Expired - Lifetime
- 2004-06-01 BR BRPI0411095A patent/BRPI0411095B8/pt not_active IP Right Cessation
- 2004-06-01 AT AT04739484T patent/ATE377008T1/de active
- 2004-06-01 DE DE602004009796T patent/DE602004009796T2/de not_active Expired - Lifetime
- 2004-06-01 EA EA200501887A patent/EA010577B1/ru not_active IP Right Cessation
- 2004-06-01 AU AU2004245208A patent/AU2004245208B2/en not_active Expired
- 2004-06-01 MX MXPA05013149A patent/MXPA05013149A/es active IP Right Grant
- 2004-06-01 HR HR20070529T patent/HRP20070529T3/xx unknown
- 2004-06-01 RS YU20050892A patent/RS53183B/sr unknown
- 2004-06-01 CA CA2527315A patent/CA2527315C/en not_active Expired - Lifetime
- 2004-06-01 CN CNB2004800156669A patent/CN100408572C/zh not_active Expired - Lifetime
- 2004-06-01 KR KR1020057023137A patent/KR100778948B1/ko not_active Expired - Lifetime
- 2004-06-01 WO PCT/EP2004/005881 patent/WO2004108701A1/en not_active Ceased
- 2004-06-01 NZ NZ543637A patent/NZ543637A/en not_active IP Right Cessation
- 2004-06-01 ES ES04739484T patent/ES2294504T3/es not_active Expired - Lifetime
- 2004-06-02 CL CL200401347A patent/CL2004001347A1/es unknown
- 2004-06-02 US US10/858,969 patent/US7332510B2/en not_active Expired - Lifetime
- 2004-06-02 PA PA20048604101A patent/PA8604101A1/es unknown
- 2004-06-02 TW TW093115811A patent/TWI338007B/zh not_active IP Right Cessation
- 2004-06-02 PE PE2004000558A patent/PE20050162A1/es active IP Right Grant
- 2004-06-03 GT GT200400117A patent/GT200400117A/es unknown
- 2004-06-03 AR ARP040101908A patent/AR044478A1/es active IP Right Grant
- 2004-06-03 MY MYPI20042150A patent/MY137272A/en unknown
- 2004-06-03 HN HN2004000208A patent/HN2004000208A/es unknown
-
2005
- 2005-05-27 MY MYPI20052424A patent/MY143353A/en unknown
- 2005-11-13 IL IL171930A patent/IL171930A/en active IP Right Grant
- 2005-11-14 CR CR8094A patent/CR8094A/es unknown
- 2005-11-18 NO NO20055465A patent/NO332143B1/no unknown
- 2005-12-01 TN TNP2005000309A patent/TNSN05309A1/fr unknown
- 2005-12-02 EC EC2005006202A patent/ECSP056202A/es unknown
- 2005-12-02 ZA ZA200509807A patent/ZA200509807B/en unknown
- 2005-12-09 MA MA28648A patent/MA27881A1/fr unknown
-
2006
- 2006-11-21 ZA ZA200609681A patent/ZA200609681B/xx unknown
- 2006-11-27 TN TNP2006000391A patent/TNSN06391A1/fr unknown
-
2007
- 2007-10-31 US US11/930,258 patent/US8481548B2/en active Active
- 2007-12-13 US US11/955,421 patent/US7973165B2/en not_active Expired - Lifetime
-
2008
- 2008-01-11 CY CY20081100047T patent/CY1107856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056202A (es) | Derivados de imidazol como antagonistas del receptor del glutamato | |
| CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
| UY28833A1 (es) | Piridonas sustituidas como inhibidores de poli (adp-ribosa)-polimerasa (parp). | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MY148429A (en) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
| NO20080475L (no) | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | |
| UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| UY28775A1 (es) | Tetrahidroquinolinonas y su uso como antagonistas de receptores de glutamato metabotropico | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
| NO20085257L (no) | Purinonderivater som HM74a-agonister | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| NO20085099L (no) | Puritonderivativer som HM74A agonister | |
| UY28144A1 (es) | Agentes terapéuticos | |
| UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
| ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
| ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| DE602005023197D1 (de) | -muscarinrezeptors | |
| DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| CR9436A (es) | Derivados de aril 1,4-pirazina sustituidos | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| UY28839A1 (es) | Agentes terapeuticos |